Omalizumab was the first, and for a long time the only available monoclonal antibody for the
add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets …

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the
US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma …

Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …

Abstract The Saudi Initiative for Asthma 2021 (SINA-2021) is the fifth version of asthma
guidelines for the diagnosis and management of asthma for adults and children, which is …

Background Allergic asthma is a long-term disorder of the airways resulting from
overexpression of immunoglobulin E (IgE) in response to environmental allergens. Patients …

This is an updated guideline for the diagnosis and management of asthma, developed by
the Saudi Initiative for Asthma (SINA) group, a subsidiary of the Saudi Thoracic Society. The …

This is the fourth version of the updated guidelines for the diagnosis and management of
asthma, developed by the Saudi Initiative for Asthma (SINA) group, a subsidiary of the Saudi …

This an updated guidelines for the diagnosis and management of asthma, developed by the
Saudi Initiative for Asthma (SINA) group, a subsidiary of the Saudi Thoracic Society. The …

Pediatric nephrotic syndrome (NS) is a common and recurrent glomerular disease in
childhood. Furthermore, 50–70% of children with NS have increased total IgE in peripheral …

Few data are available on the proportion of asthmatics achieving a good asthma control
(according GINA guidelines) and on the level of airway inflammation during omalizumab …